PubMed Health⌕ Search

Biomedical subjects

M Vĕtr

Publications and source records attributed to M Vĕtr.

18 recordsLinked to original sources
PubMed1994

[Prolactinomas].

Explore the source record for details and available documents.

Adult↗
PubMed1993

Low dose spironolactone in the treatment of female hyperandrogenemia and hirsutism.

Thirty one women with hyperandrogenism, clinically divided into polycystic ovary syndrome (PCOS)--28 women and idiopathic hirsutism (I.H.)--3 women, were treated with low dose spironolactone (50 mg or 75 mg daily) for average five months. There was an excellent clinical response in 19 (61%), incomplete response in 8 (26%), no response in 5 women. Six of 18 patients with sterility became pregnant during the one year after treatment and delivered a healthy infant at term. Two patients dropped out of the trial because of intolerance of the therapy. Remarkable change of the menstrual pattern characterised as polymenorrhea was major side effect of the therapy. Other side effects were not problem. Spironolactone caused statistically significant reduction in testosterone, luteinizing hormone and prolactin values at the end of the treatment. Our results demonstrate that low-dose spironolactone is effective in the treatment of hyperandrogenism in women.

Adolescent↗
PubMed1991

Monitoring of ovulation by ultrasound.

Ovarian growth was monitored by ultrasound and plasma hormonal levels (E2, LH, FSH, progesterone) in 124 cycles of 71 patients. Providing a direct view of follicular maturation, ultrasound can help in the determination of the best time for the induction of ovulation. Examining the speed of follicular growth we can predict some ovulatory dysfunction.

Female↗
PubMed1991

Metoclopramide test in women with PCO syndrome after ovarian wedge resection.

Afternoon serum PRL levels and PRL responsiveness to metoclopramide (MCP) were determined in 36 women, aged 30.5 +/- 4.5, with normoprolactinemic anovulation. All women underwent a bilateral ovarian wedge resection with diagnosis polycystic ovarian disease (PCO) 2.9 +/- 2.0 years ago. After operation only four women had been pregnant. A bolus i.v. dose of 10 mg metoclopramide was given and serum PRL was estimated before, 30 and 60 min. after MCP administration. Diurnal serum PRL levels were approximately 9 ng in all patients. The PCO patients were classified into 2 groups in terms of the responsiveness to metoclopramide test. MCP induces rapid and marked elevation in serum PRL levels in all subjects. The maximum post MCP PRL value in the group I patients (n = 16) was 143.0 +/- 37.7 ng/ml, which was significantly higher than the maximum value in the II group patients (104.3 +/- 32.5 ng/ml) (P less than 0.005). Nine (56.2%) of the I group patients had maximum PRL values higher than 150 ng/ml; the proportion was statistically higher than 10 percent maximum PRL values in the group II (P less than 0.01). This finding suggests that the patients who had enhanced PRL responsiveness to MCP test have latent hyperprolactinemia, which can not be detected by analyzing PRL levels in blood samples taken randomly. This latent hyperprolactinemia presumably might be normalized by dopamine agonist therapy, resulting in resumption of ovulatory cycles in these women.

Adult↗
PubMed1990

Terguride in the treatment of hyperprolactinemia.

Thirty-two women with ovarian dysfunction due to hyperprolactinemia were treated with a new derivative of lisuride-terguride. Twenty-three patients were treated for infertility. A microadenoma was confirmed in five, and three other patients had had a macroprolactinoma surgically removed. The finding in one of the patients was diagnosed as the syndrome of empty sella. Galactorrhea was present in 18 women. The duration of treatment ranged from 2 to 33 months. The determination of therapeutic dosages was based on individual responses on the prolactin levels within a range from 0.1 to 4.5 mg per day. Increased prolactin levels were successfully normalized in twenty-one treated patients. Regular periods were reappeared in 59% of the women. Thirteen (56%) became pregnant, seven gave birth to healthy babies, two of the patients aborted in the first trimester. Four women are still in later stages of pregnancy. Galactorrhea disappeared in 56% of the patients, being markedly inhibited in the remaining ones. In two cases, microadenoma disappeared after treatment, and in those after surgery the postoperative findings were decreased, in one patients there is no alteration in the pathology. Side effects were seen in 34% of the patients, being mostly mild in nature, and including in most cases nausea, headache and stomach pain. The complaints were transient, receding after prolonged treatment.

Adolescent↗
PubMed1989

Hirsutism--a low dose spironolactone therapy.

Total testosterone, dehydroepiandrosterone sulfate, prolactin and estradiol were assayed in 78 women, clinically divided into idiopathic hirsutism (I. H.)-17 women and polycystic ovary syndrome (PCO) - 61 women, with the latter group having menstrual irregularity dating almost back to the menarche. The serum testosterone measurement was found to be not sensitive in detecting abnormalities in testosterone production. Only 24 (39%) of the women with polycystic ovary syndrome and 5 (29%) of the women with idiopathic hirsutism had elevated serum testosterone. In statistical analysis the serum testosterone was greater (P less than 0.05) in women with polycystic ovary syndrome without hirsutism than in idiopathic hirsutism and PCO with hirsutism. There were not significant differences between the mean levels of prolactin, dehydroepiandrosterone sulfate and estradiol. Twelve women, with hirsutism, were treated with low dose spironolactone (75 mg daily) for six months. There was an excellent clinical response in 7 (58%), incomplete response in one, no response in 4 women. Two patients dropped out of the trial because of ineffectiveness of the therapy after three months. Side effects were not major problem. Spironolactone caused statistically significant reduction in testosterone values after 6 months of treatment. Our results demonstrate that low-dose spironolactone is effective in the treatment of hirsutism.

Adolescent↗